U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C16H23NO2.C6H8O7
Molecular Weight 453.4828
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHOHEPTAZINE CITRATE

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CCOC(=O)C1(CCCN(C)CC1)C2=CC=CC=C2

InChI

InChIKey=KCVHFFSPDODYOG-UHFFFAOYSA-N
InChI=1S/C16H23NO2.C6H8O7/c1-3-19-15(18)16(14-8-5-4-6-9-14)10-7-12-17(2)13-11-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-6,8-9H,3,7,10-13H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI

Description

Ethoheptazine is an analgesic, which belongs to the proheptazine group. It was used either alone (Zactane trade name) or in combination with meprobamate and aspirin (Equagesic) for the pain relief in patients with headache or musculoskeletal disorders. Currently all mediactions containing ethoheptazine are withdrawn from the market. The exact target of ethoheptazine is unknow, but it is believed that it may have modulatory effect on opioid receptors.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
EQUAGESIC
Primary
EQUAGESIC

Doses

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
The usual dose is 1 or 2 tablets three or four times daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown